Cialis NDA Issues Include Back Pain At 20 Mg Dose, FDA Documents Show
Executive Summary
FDA's safety questions about Lilly/Icos' erectile dysfunction agent Cialis focus on back pain reported at the starting dose initially proposed by the companies
You may also be interested in...
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
Bayer Repinotan Development Slowed By Dosing Issue, FDA Documents Show
Bayer will use a loading dose of the stroke drug repinotan in Phase III trials following discussions with FDA over how best to maximize treatment response, agency documents show